Europe Clinical Trial Supplies Market
Tamanho do mercado em biliões de dólares
CAGR : %
Período de previsão |
2023 –2029 |
Tamanho do mercado (ano base ) | |
Tamanho do mercado ( Ano de previsão) | USD 1,835.70 |
CAGR |
|
Principais participantes do mercado |
|
>Mercado europeu de fornecimentos para ensaios clínicos, por serviços (armazenamento, fabrico, embalagem e rotulagem), fase clínica (fase III, fase II, fase IV, fase I), utilizações terapêuticas (oncologia, doenças cardiovasculares, dermatologia, distúrbios metabólicos, doenças infeciosas, Doenças respiratórias , perturbações do SNC e mentais, perturbações do sangue, outras), utilizador final (organizações de investigação por contrato, empresas farmacêuticas e de biotecnologia), tendências do setor e previsão para 2029.
Análise de Mercado e Insights : Mercado Europeu de Material para Ensaios Clínicos
Espera-se que o mercado europeu de fornecimentos para ensaios clínicos ganhe crescimento de mercado no período de previsão de 2022 a 2029. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 7,8% no período de previsão de 2022 a 2029 e prevê-se que atinja os 1.835,70 milhões de USD até 2029. O principal fator que impulsiona o crescimento do mercado de fornecimento de ensaios clínicos é o aumento da procura em ensaios clínicos em todo o mundo, aumentando a incidência de doenças, fundos governamentais para investimentos em I&D e desenvolvimento de novos tratamentos, tais como medicamentos personalizados liderando os fornecimentos para ensaios clínicos mercado cresça no futuro.
O ensaio clínico é um estudo de investigação que determina se uma estratégia, tratamento ou dispositivo médico é seguro, eficaz e útil para uso humano. Estes estudos ajudam a descobrir quais as abordagens médicas melhores para determinadas doenças. Um ensaio clínico fornece os melhores dados para efeitos de tomada de decisão em cuidados de saúde.
O objetivo do ensaio clínico é estudar padrões científicos rigorosos. Estes padrões protegem os doentes e ajudam na produção de resultados de estudos fiáveis.
Os ensaios clínicos são a última etapa do desenvolvimento de medicamentos num longo e cuidadoso processo de investigação realizado por cientistas ou investigadores para uma doença específica, seja um medicamento ou dispositivo médico. O processo de desenvolvimento de medicamentos começa geralmente num laboratório, onde os cientistas desenvolvem e testam primeiro novas ideias relacionadas com o tratamento de doenças.
O relatório do mercado de fornecimentos para ensaios clínicos da Europa fornece detalhes de quota de mercado, novos desenvolvimentos e análise de pipeline de produtos, impacto dos participantes do mercado doméstico e localizado, analisa as oportunidades em termos de bolsas de receitas emergentes, alterações nas regulamentações de mercado, aprovações de produtos , decisões estratégicas, produtos lançamentos, expansões geográficas e inovações tecnológicas no mercado. Para compreender a análise e o cenário do mercado contacte-nos para um Analyst Brief, a nossa equipa irá ajudá-lo a criar uma solução de impacto na receita para atingir o objetivo desejado.
Métrica de reporte |
Detalhes |
Período de previsão |
2022 a 2029 |
Ano base |
2021 |
Anos históricos |
2020 (personalizável para 2019 - 2014) |
Unidades Quantitativas |
Receita em milhões de dólares, preços em dólares |
Segmentos cobertos |
Por Serviços (Armazenamento, Fabrico, Acondicionamento e Rotulagem), Fase Clínica (Fase III, Fase II, Fase IV, Fase I), Usos Terapêuticos (Oncologia, Doenças Cardiovasculares, Dermatologia, Perturbações Metabólicas, Doenças Infeciosas, Doenças Respiratórias, SNC e Mentais Perturbações, perturbações sanguíneas, outros), por utilizador final (organizações de investigação contratadas, empresas farmacêuticas e de biotecnologia) |
Países abrangidos |
Alemanha, França, Reino Unido, Holanda, Suíça, Bélgica, Rússia, Itália, Espanha, Turquia, Resto da Europa na Europa |
Participantes do mercado abrangidos |
Movianto (EUA), Sharp (EUA), Thermo Fisher Scientific Inc., (EUA), Catalent, Inc (EUA), PCI Pharma Services (EUA), Almac Group (Reino Unido), PAREXEL International Corporation (EUA), Bionical Ltd . |
Dinâmica do mercado de fornecimentos para ensaios clínicos
Motoristas
- Aumento da procura por ensaios clínicos em todo o mundo
A crescente procura de ensaios clínicos tem sido de 82% apenas nos países em desenvolvimento, como a América do Norte, a Europa e a Ásia. Estes medicamentos estão disponíveis no mercado após ensaio clínico, pelo que todas as empresas realizam, na sua maioria, ensaios clínicos dependendo do tipo de medicamento ou dispositivo. e, portanto, atuar como um grande impulsionador que resultará na expansão da taxa de crescimento do mercado de tratamento.
- Aumento da incidência de doenças crónicas
A elevada prevalência de doenças crónicas devido ao rápido aumento da população e das infecções entre as pessoas pode ser observada em todo o mundo. Estas doenças contribuem com um papel importante no campo dos ensaios clínicos para o desenvolvimento de medicamentos. O medicamento necessita de passar por toda a fase clínica padrão para estar disponível antes do consumo humano. Assim, para tratar estas doenças crónicas em humanos, o medicamento tem de ser seguro.
- Fundos governamentais em investimentos em I&D
Os instrumentos, a força de trabalho, a gestão médica em caso de danos para os investigadores, o seguro, o transporte, as taxas da comissão de ética, o tratamento de dados e outros consumíveis levam a um grande envolvimento de custos nos ensaios clínicos. Os ensaios clínicos são a avaliação de ideias de prevenção e tratamento de doenças que irão aumentar ainda mais o crescimento do mercado de tratamento.
Oportunidades
- Aumento dos ensaios de desenvolvimento de novos medicamentos nos países emergentes
O ensaio clínico para a eficácia dos medicamentos é a chave primária para o desenvolvimento de medicamentos para o tratamento de doenças antes do lançamento no mercado para consumo humano. Além disso, os novos medicamentos têm de cumprir extensões de licença e normas internacionais antes de serem vendidos e distribuídos. O aumento da prevalência e da incidência de doenças e o aumento do número de doentes são os factores que conduziram às tendências emergentes de ensaios clínicos para o desenvolvimento de medicamentos nos países em desenvolvimento durante o período passado.
Also, governments in emerging markets (China, Brazil, Russia, India, and South Africa) reform public healthcare and grant more accessible access to medicine. These two factors working in unison mean greater freedom for market developments and increased innovation in clinical research in emerging markets.
Restraints/Challenges
Adverse drug reactions are the unwanted or harmful effects that can be experienced after the administration of a drug under normal conditions of use in humans. The drug reactions generally occur in jaundice, anaemia, rashes and lead to a decrease in the white blood cell count, damaged kidney, and nerve injury that caused impaired vision or hearing.
Many of the adverse effects may be ascertained from physical examinations during the clinical phase of testing. Thus, reporting adverse effects during clinical trial is the major leading restraints factor for the supplies market. Despite high time and cost investments for developing biologics and new drugs, it is estimated that lower procedure time and rate for approval of drug is creating a biggest challenge for the market, which may hamper the market growth.
This clinical trial supplies market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on clinical trial supplies market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In February 2022, Thermo Fisher Scientific has announced partnership with Medidata to optimize clinical research site selection and speed patient enrollment in clinical trial. This improves clinical trial planning and execution to accelerate clinical trial in which datasets have been generated from 26,000 clinical trial and nearly 8 million patients in more than 140 countries across the globe
Europe Clinical Trial Supplies Market Scope
Europe clinical trial supplies market is categorized based on services, clinical phase, therapeutic uses and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Service
- Manufacturing
- Distribution
- Storage
- Packaging and Labelling
On the basis of services the Europe clinical trial supplies market is segmented into manufacturing, distribution, storage, and packaging and labelling.
Clinical Phase
- Phase I
- Phase II
- Phase III
- Phase IV
On the basis of clinical phase the Europe clinical trial supplies market is segmented into phase I, phase II, phase III and phase IV.
Therapeutic Uses
- Oncology
- CNS
- Mental Disorders
- Cardiovascular Diseases
- Infectious Diseases
- Respiratory Diseases
- Blood Disorder
- Dermatology
- Others
On the basis of therapeutic uses, the Europe clinical trial supplies market is segmented into oncology, CNS and mental disorders, cardiovascular diseases, infectious disease, respiratory diseases, metabolic disorders, blood disorders, dermatology and others.
End User
- Contract research organizations
- Pharmaceutical and biotechnology companies
On the basis of end user, the Europe clinical trial supplies market is segmented into contract research organizations and pharmaceutical and biotechnology companies.
Clinical Trial Supplies Market Regional Analysis/Insights
The Europe clinical trial supplies market is further segmented into major countries such as Germany, France, U.K., Italy, Spain, Russia, Belgium, Turkey, Netherlands, Switzerland, rest of Europe.
U.K. dominates the Europe clinical trial supplies market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period of 2022-2029. This is due to the presence of major key players investing in R&D for the better service of clinical trial supplies and well-developed healthcare infrastructure in this region.
The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of global brands and their challenges faced due to high competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Europe Clinical Trial Supplies Market Share Analysis
Europe clinical trial supplies market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trial pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to clinical trial supplies market.
Os principais participantes proeminentes que operam no mercado europeu de fornecimentos para ensaios clínicos são a Movianto (EUA), Sharp (EUA), Thermo Fisher Scientific Inc., (EUA), Catalent, Inc (EUA), PCI Pharma Services (EUA), Almac Group ( Reino Unido), PAREXEL International Corporation (EUA), Bionical Ltd. (Reino Unido), Alium Medical Limited (Reino Unido), MYODERM (Reino Unido), Clinigen Group plc (Reino Unido), Ancillare, LP (EUA), SIRO Clinpharm (Índia) CLÍNICOS SUPRIMENTOS MANAGEMENT HOLDINGS, INC. (EUA) Biocair (Reino Unido) e entre outros.
Metodologia de Investigação : Mercado Europeu de Material para Ensaios Clínicos
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Além disso, os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise da quota de mercado da empresa, padrões de medição, GlobalVsRegional e análise de participação dos fornecedores. Solicite a chamada do analista em caso de dúvidas adicionais.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE CLINICAL TRIAL SUPPLIES MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 SERVICES LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTERS FIVE FORCES
5 EUROPE CLINICAL TRIAL SUPPLIES MARKET: REGULATORY SCENARIO
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING DEMAND FOR CLINICAL TRIALS WORLDWIDE
6.1.2 INCREASING INCIDENCE OF CHRONIC DISEASES
6.1.3 GOVERNMENT FUNDS IN R&D INVESTMENTS
6.1.4 ADVANCEMENT OF TECHNOLOGY IN CLINICAL TRIALS SUPPLIES
6.2 RESTRAINTS
6.2.1 ADVERSE EFFECTS OF CLINICAL TRIALS
6.2.2 TRANSPORTATION ISSUE IN CLINICAL TRIAL SUPPLIES
6.2.3 HIGH COST ASSOCIATED WITH THE CLINICAL TRIALS
6.3 OPPORTUNITIES
6.3.1 INCREASING NEW DRUG DEVELOPMENT TRIALS IN EMERGING COUNTRIES
6.3.2 INCREASING DEMAND FOR INNOVATIVE SOLUTIONS IN CLINICAL TRIALS SERVICES
6.3.3 EVOLUTION IN SUPPLY CHAIN MANAGEMENT FOR CLINICAL TRIALS
6.4 CHALLENGES
6.4.1 LOWER PROCEDURE TIME OF CLINICAL TRIALS APPROVAL
6.4.2 LACK OF SKILLED PERSON TO OPERATE DEVICES DURING CLINICAL TRIALS
7 EUROPE CLINICAL TRIAL SUPPLIES MARKET, BY SERVICES
7.1 OVERVIEW
7.2 STORAGE
7.3 MANUFACTURING
7.4 PACKAGING AND LABELLING
7.5 DISTRIBUTION
8 EUROPE CLINICAL TRIAL SUPPLIES MARKET, BY CLINICAL PHASES
8.1 OVERVIEW
8.2 PHASE III
8.3 PHASE II
8.4 PHASE IV
8.5 PHASE I
9 EUROPE CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC USE
9.1 OVERVIEW
9.2 ONCOLOGY
9.3 CARDIOVASCULAR DISEASES
9.4 DERMATOLOGY
9.5 METABOLIC DISORDERS
9.6 INFECTIOUS DISEASES
9.7 RESPIRATORY DISEASES
9.8 CNS AND MENTAL DISORDERS
9.9 BLOOD DISORDERS
9.1 OTHERS
10 EUROPE CLINICAL TRIAL SUPPLIES MARKET, BY END USER
10.1 OVERVIEW
10.2 CONTRACT RESEARCH ORGANIZATIONS
10.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
11 EUROPE CLINICAL TRIAL SUPPLIES MARKET, BY REGION
11.1 EUROPE
11.1.1 GERMANY
11.1.2 FRANCE
11.1.3 U.K.
11.1.4 ITALY
11.1.5 SPAIN
11.1.6 NETHERLANDS
11.1.7 RUSSIA
11.1.8 BELGIUM
11.1.9 TURKEY
11.1.10 SWITZERLAND
11.1.11 REST OF EUROPE
12 EUROPE CLINICAL TRIAL SUPPLIES MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: EUROPE
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 THERMO FISHER SCIENTIFIC INC.
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENT
14.1.5.1 PARTNERSHIP
14.2 ALMAC GROUP
14.2.1 COMPANY SNAPSHOT
14.2.2 COMPANY SHARE ANALYSIS
14.2.3 PRODUCT PORTFOLIO
14.2.4 RECENT DEVELOPMENTS
14.3 CATALENT INC.
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 SERVICE PORTFOLIO
14.3.5 RECENT DEVELOPMENT
14.3.5.1 SERVICE EXPANSION
14.4 CLINIGEN GROUP PLC
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENT
14.4.5.1 PARTNERSHIP
14.5 MOVIANTO
14.5.1 COMPANY SNAPSHOT
14.5.2 COMPANY SHARE ANALYSIS
14.5.3 SERVICE PORTFOLIO
14.5.4 RECENT DEVELOPMENT
14.5.4.1 ACQUISITION
14.6 PCI PHARMA SERVICES
14.6.1 COMPANY SNAPSHOT
14.6.2 SERVICE PORTFOLIO
14.6.3 RECENT DEVELOPMENTS
14.7 SHARP
14.7.1 COMPANY SNAPSHOT
14.7.2 SERVICE PORTFOLIO
14.7.3 RECENT DEVELOPMENT
14.8 ALIUM MEDICAL LIMITED
14.8.1 COMPANY SNAPSHOT
14.8.2 SERVICE PORTFOLIO
14.8.3 RECENT DEVELOPMENT
14.9 ANCILLARE, LP
14.9.1 COMPANY SNAPSHOT
14.9.2 SERVICE PORTFOLIO
14.9.3 RECENT DEVELOPMENT
14.1 BIOCAIR
14.10.1 COMPANY SNAPSHOT
14.10.2 SERVICE PORTFOLIO
14.10.3 RECENT DEVELOPMENTS
14.11 BIONICAL LTD.
14.11.1 COMPANY SNAPSHOT
14.11.2 SERVICE PORTFOLIO
14.11.3 RECENT DEVELOPMENT
14.11.3.1 SERVICE LAUNCH
14.12 CLINICAL SUPPLIES MANAGEMENT HOLDINGS,INC
14.12.1 COMPANY SNAPSHOT
14.12.2 SERVICE PORTFOLIO
14.12.3 RECENT DEVELOPMENT
14.13 KLIFO
14.13.1 COMPANY SNAPSHOT
14.13.2 SERVICE PORTFOLIO
14.13.3 RECENT DEVELOPMENTS
14.13.3.1 ACQUISTION
14.14 MYONEX
14.14.1 COMPANY SNAPSHOT
14.14.2 SERVICE PORTFOLIO
14.14.3 RECENT DEVELOPMENT
14.15 PAREXEL INTERNATIONAL CORPORATION
14.15.1 COMPANY SNAPSHOT
14.15.2 SERVICE PORTFOLIO
14.15.3 RECENT DEVELOPMENT
14.15.3.1 COLLABORATION
14.16 SIRO CLINPHARM PRIVATE LIMITED
14.16.1 COMPANY SNAPSHOT
14.16.2 SERVICE PORTFOLIO
14.16.3 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
Lista de Tabela
TABLE 1 LOCATIONS OF REGISTERED STUDIES
TABLE 2 EUROPE CLINICAL TRIAL SUPPLIES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 3 EUROPE STORAGE IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 EUROPE MANUFACTURING IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 EUROPE PACKAGING AND LABELLING IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 EUROPE DISTRIBUTION IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 EUROPE CLINICAL TRIAL SUPPLIES MARKET, BY CLINICAL PHASE, 2020-2029 (USD MILLION)
TABLE 8 EUROPE PHASE III IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 EUROPE PHASE II IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 EUROPE PHASE IV IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 EUROPE PHASE I IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 EUROPE CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC USE, 2020-2029 (USD MILLION)
TABLE 13 EUROPE ONCOLOGY IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 EUROPE CARDIOVASCULAR DISEASES IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 EUROPE DERMATOLOGY IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 EUROPE METABOLIC DISORDERS IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 EUROPE INFECTIOUS DISEASES IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 EUROPE RESPIRATORY DISEASES IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 EUROPE CNS AND MENTAL DISORDERS IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 EUROPE BLOOD DISORDERS IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 EUROPE OTHERS IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 EUROPE CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 23 EUROPE CONTRACT RESEARCH ORGANIZATIONS IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 EUROPE PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN CLINICAL TRIAL SUPPLIES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 EUROPE CLINICAL TRIAL SUPPLIES MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 26 EUROPE CLINICAL TRIAL SUPPLIES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 27 EUROPE CLINICAL TRIAL SUPPLIES MARKET, BY CLINICAL PHASE, 2020-2029 (USD MILLION)
TABLE 28 EUROPE CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC USE, 2020-2029 (USD MILLION)
TABLE 29 EUROPE CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 30 GERMANY CLINICAL TRIAL SUPPLIES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 31 GERMANY CLINICAL TRIAL SUPPLIES MARKET, BY CLINICAL PHASE, 2020-2029 (USD MILLION)
TABLE 32 GERMANY CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC USE, 2020-2029 (USD MILLION)
TABLE 33 GERMANY CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 34 FRANCE CLINICAL TRIAL SUPPLIES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 35 FRANCE CLINICAL TRIAL SUPPLIES MARKET, BY CLINICAL PHASE, 2020-2029 (USD MILLION)
TABLE 36 FRANCE CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC USE, 2020-2029 (USD MILLION)
TABLE 37 FRANCE CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 38 U.K. CLINICAL TRIAL SUPPLIES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 39 U.K. CLINICAL TRIAL SUPPLIES MARKET, BY CLINICAL PHASE, 2020-2029 (USD MILLION)
TABLE 40 U.K. CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC USE, 2020-2029 (USD MILLION)
TABLE 41 U.K. CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 42 ITALY CLINICAL TRIAL SUPPLIES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 43 ITALY CLINICAL TRIAL SUPPLIES MARKET, BY CLINICAL PHASE, 2020-2029 (USD MILLION)
TABLE 44 ITALY CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC USE, 2020-2029 (USD MILLION)
TABLE 45 ITALY CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 46 SPAIN CLINICAL TRIAL SUPPLIES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 47 SPAIN CLINICAL TRIAL SUPPLIES MARKET, BY CLINICAL PHASE, 2020-2029 (USD MILLION)
TABLE 48 SPAIN CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC USE, 2020-2029 (USD MILLION)
TABLE 49 SPAIN CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 50 NETHERLANDS CLINICAL TRIAL SUPPLIES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 51 NETHERLANDS CLINICAL TRIAL SUPPLIES MARKET, BY CLINICAL PHASE, 2020-2029 (USD MILLION)
TABLE 52 NETHERLANDS CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC USE, 2020-2029 (USD MILLION)
TABLE 53 NETHERLANDS CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 54 RUSSIA CLINICAL TRIAL SUPPLIES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 55 RUSSIA CLINICAL TRIAL SUPPLIES MARKET, BY CLINICAL PHASE, 2020-2029 (USD MILLION)
TABLE 56 RUSSIA CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC USE, 2020-2029 (USD MILLION)
TABLE 57 RUSSIA CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 58 BELGIUM CLINICAL TRIAL SUPPLIES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 59 BELGIUM CLINICAL TRIAL SUPPLIES MARKET, BY CLINICAL PHASE, 2020-2029 (USD MILLION)
TABLE 60 BELGIUM CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC USE, 2020-2029 (USD MILLION)
TABLE 61 BELGIUM CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 62 TURKEY CLINICAL TRIAL SUPPLIES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 63 TURKEY CLINICAL TRIAL SUPPLIES MARKET, BY CLINICAL PHASE, 2020-2029 (USD MILLION)
TABLE 64 TURKEY CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC USE, 2020-2029 (USD MILLION)
TABLE 65 TURKEY CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 66 SWITZERLAND CLINICAL TRIAL SUPPLIES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
TABLE 67 SWITZERLAND CLINICAL TRIAL SUPPLIES MARKET, BY CLINICAL PHASE, 2020-2029 (USD MILLION)
TABLE 68 SWITZERLAND CLINICAL TRIAL SUPPLIES MARKET, BY THERAPEUTIC USE, 2020-2029 (USD MILLION)
TABLE 69 SWITZERLAND CLINICAL TRIAL SUPPLIES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 70 REST OF EUROPE CLINICAL TRIAL SUPPLIES MARKET, BY SERVICES, 2020-2029 (USD MILLION)
Lista de Figura
FIGURE 1 EUROPE CLINICAL TRIAL SUPLLIES MARKET: SEGMENTATION
FIGURE 2 EUROPE CLINICAL TRIAL SUPPLIES MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE CLINICAL TRIAL SUPPLIES MARKET: DROC ANALYSIS
FIGURE 4 EUROPE CLINICAL TRIAL SUPPLIES MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE CLINICAL TRIAL SUPPLIES MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE CLINICAL TRIAL SUPLLIES MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE CLINICAL TRIAL SUPPLIES MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE CLINICAL TRIAL SUPPLIES MARKET: DBMR VENDOR SHARE ANALYSIS
FIGURE 9 EUROPE CLINICAL TRIAL SUPPLIES MARKET: SEGMENTATION
FIGURE 10 NORTH AMERICA IS EXPECTED TO DOMINATE THE EUROPE CLINICAL TRIAL SUPPLIES MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 11 RISING DEMAND FOR CLINICAL TRIALS WORLDWIDE AND INCREASING INCIDENCES OF DISEASES IS DRIVING THE EUROPE CLINICAL TRIAL SUPPLIES MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 STORAGE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE CLINICAL TRIAL SUPPLIES MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE CLINICAL TRIAL SUPPLIES MARKET
FIGURE 14 EUROPE CLINICAL TRIAL SUPPLIES MARKET: BY SERVICES, 2021
FIGURE 15 EUROPE CLINICAL TRIAL SUPPLIES MARKET: BY SERVICES, 2022-2029 (USD MILLION)
FIGURE 16 EUROPE CLINICAL TRIAL SUPPLIES MARKET: BY SERVICES, CAGR (2022-2029)
FIGURE 17 EUROPE CLINICAL TRIAL SUPPLIES MARKET: BY SERVICES, LIFELINE CURVE
FIGURE 18 EUROPE CLINICAL TRIAL SUPPLIES MARKET: BY CLINICAL PHASE, 2021
FIGURE 19 EUROPE CLINICAL TRIAL SUPPLIES MARKET: BY CLINICAL PHASE, 2022-2029 (USD MILLION)
FIGURE 20 EUROPE CLINICAL TRIAL SUPPLIES MARKET: BY CLINICAL PHASE, CAGR (2022-2029)
FIGURE 21 EUROPE CLINICAL TRIAL SUPPLIES MARKET: BY CLINICAL PHASE, LIFELINE CURVE
FIGURE 22 EUROPE CLINICAL TRIAL SUPPLIES MARKET: BY THERAPEUTIC USE, 2021
FIGURE 23 EUROPE CLINICAL TRIAL SUPPLIES MARKET: BY THERAPEUTIC USE, 2022-2029 (USD MILLION)
FIGURE 24 EUROPE CLINICAL TRIAL SUPPLIES MARKET: BY THERAPEUTIC USE, CAGR (2022-2029)
FIGURE 25 EUROPE CLINICAL TRIAL SUPPLIES MARKET: BY THERAPEUTIC USE, LIFELINE CURVE
FIGURE 26 EUROPE CLINICAL TRIAL SUPPLIES MARKET: BY END USER, 2021
FIGURE 27 EUROPE CLINICAL TRIAL SUPPLIES MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 28 EUROPE CLINICAL TRIAL SUPPLIES MARKET: BY END USER, CAGR (2022-2029)
FIGURE 29 EUROPE CLINICAL TRIAL SUPPLIES MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 EUROPE CLINICAL TRIAL SUPPLIES MARKET: SNAPSHOT (2021)
FIGURE 31 EUROPE CLINICAL TRIAL SUPPLIES MARKET: BY COUNTRY (2021)
FIGURE 32 EUROPE CLINICAL TRIAL SUPPLIES MARKET: BY COUNTRY (2022 & 2029)
FIGURE 33 EUROPE CLINICAL TRIAL SUPPLIES MARKET: BY COUNTRY (2021 & 2029)
FIGURE 34 EUROPE CLINICAL TRIAL SUPPLIES MARKET: BY SERVICES (2022-2029)
FIGURE 35 EUROPE CLINICAL TRIAL SUPPLIES MARKET: COMPANY SHARE 2021 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.